(Q30685335)

26 June 2017

Imaging glutamate in schizophrenia: review of findings and implications for drug discovery (English)

1 reference

26 June 2017

0 references

1 reference

E M P Poels

1

1 reference

26 June 2017

L S Kegeles

2

1 reference

26 June 2017

J T Kantrowitz

3

1 reference

26 June 2017

M Slifstein

4

1 reference

26 June 2017

D C Javitt

5

1 reference

26 June 2017

J A Lieberman

6

1 reference

26 June 2017

A Abi-Dargham

7

1 reference

26 June 2017

R R Girgis

8

1 reference

26 June 2017

language of work or name

English

0 references

publication date

29 October 2013

1 reference

26 June 2017

1 reference

26 June 2017

19

1 reference

26 June 2017

1

1 reference

26 June 2017

20-29

1 reference

Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents

26 June 2017

1 reference

https://api.crossref.org/works/10.1038%2FMP.2013.136

Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2013.136

Contribution of cystine-glutamate antiporters to the psychotomimetic effects of phencyclidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2013.136

N-methyl-d-aspartate (NMDA) receptor dysfunction or dysregulation: the final common pathway on the road to schizophrenia?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2013.136

Meta-analysis of the efficacy of adjunctive NMDA receptor modulators in chronic schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2013.136

Selective GlyT1 inhibitors: discovery of [4-(3-fluoro-5-trifluoromethylpyridin-2-yl)piperazin-1-yl][5-methanesulfonyl-2-((S)-2,2,2-trifluoro-1-methylethoxy)phenyl]methanone (RG1678), a promising novel medicine to treat schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2013.136

Translating glutamate: from pathophysiology to treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2013.136

Model psychoses and schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2013.136

Recent advances in the phencyclidine model of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2013.136

Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2013.136

Comparison of ketamine-induced thought disorder in healthy volunteers and thought disorder in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2013.136

Effects of ketamine in normal and schizophrenic volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2013.136

Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2013.136

Provocative tests with psychostimulant drugs in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2013.136

Presynaptic dopamine function in striatum of neuroleptic-naive schizophrenic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2013.136

Presynaptic dopaminergic dysfunction in schizophrenia: a positron emission tomographic [18F]fluorodopa study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2013.136

Elevated dopa decarboxylase activity in living brain of patients with psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2013.136

Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2013.136

Alterations of benzodiazepine receptors in type II alcoholic subjects measured with SPECT and [123I]iomazenil.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2013.136

Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2013.136

Increased baseline occupancy of D2 receptors by dopamine in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2013.136

Implications of normal brain development for the pathogenesis of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2013.136

Dopamine in schizophrenia: a review and reconceptualization

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2013.136

Increased prefrontal cortical D₁ receptors in drug naive patients with schizophrenia: a PET study with [¹¹C]NNC112.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2013.136

Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2013.136

PET study of D(1) dopamine receptor binding in neuroleptic-naive patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2013.136

Modulation of striatal dopamine release by glycine transport inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2013.136

Glutamate modulation of dopamine measured in vivo with positron emission tomography (PET) and 11C-raclopride in normal human subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2013.136

Effects of NMDA antagonism on striatal dopamine release in healthy subjects: application of a novel PET approach.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2013.136

Effects of (S)-ketamine on striatal dopamine: a [11C]raclopride PET study of a model psychosis in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2013.136

Ketamine does not decrease striatal dopamine D2 receptor binding in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2013.136

NMDA antagonist effects on striatal dopamine release: positron emission tomography studies in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2013.136

Cortical glutamate-dopamine interaction and ketamine-induced psychotic symptoms in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2013.136

Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: implications for schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2013.136

Altered prefrontal dopaminergic function in chronic recreational ketamine users

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2013.136

Learning potential on the WCST in schizophrenia is related to the neuronal integrity of the anterior cingulate cortex as measured by proton magnetic resonance spectroscopy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2013.136

Proton magnetic resonance spectroscopy in 22q11 deletion syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2013.136

Proton magnetic resonance spectroscopy study of brain metabolite changes after antipsychotic treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2013.136

White matter alterations in deficit schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2013.136

Proton magnetic resonance spectroscopy and thought disorder in childhood schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2013.136

Proton magnetic resonance spectroscopy in subjects with high genetic risk of schizophrenia: investigation of anterior cingulate, dorsolateral prefrontal cortex and thalamus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2013.136

Elevated prefrontal cortex γ-aminobutyric acid and glutamate-glutamine levels in schizophrenia measured in vivo with proton magnetic resonance spectroscopy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2013.136

Increased prefrontal and hippocampal glutamate concentration in schizophrenia: evidence from a magnetic resonance spectroscopy study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2013.136

Neurochemical and structural correlates of executive dysfunction in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2013.136

Evidence for glutamatergic neuronal dysfunction in the prefrontal cortex in chronic but not in first-episode patients with schizophrenia: a proton magnetic resonance spectroscopy study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2013.136

Cognitive impairment and in vivo metabolites in first-episode neuroleptic-naive and chronic medicated schizophrenic patients: a proton magnetic resonance spectroscopy study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2013.136

Glutamate and glutamine measured with 4.0 T proton MRS in never-treated patients with schizophrenia and healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2013.136

Measurement of glutamate and glutamine in the medial prefrontal cortex of never-treated schizophrenic patients and healthy controls by proton magnetic resonance spectroscopy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2013.136

Longitudinal grey-matter and glutamatergic losses in first-episode schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2013.136

Glutamate as a marker of cognitive function in schizophrenia: a proton spectroscopic imaging study at 4 Tesla.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2013.136

Abnormal glutamatergic neurotransmission and neuronal-glial interactions in acute mania

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2013.136

Evidence for neuronal dysfunction in the anterior cingulate of patients with schizophrenia: a proton magnetic resonance spectroscopy study at 3 T.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2013.136

Regional decoupling of N-acetyl-aspartate and glutamate in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2013.136

1H-MRS at 4 tesla in minimally treated early schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2013.136

Assessments of function and biochemistry of the anterior cingulate cortex in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2013.136

The effect of risperidone on metabolite measures in the frontal lobe, temporal lobe, and thalamus in schizophrenic patients. A proton magnetic resonance spectroscopy (1H MRS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2013.136

Anterior cingulate glutamate levels related to clinical status following treatment in first-episode schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2013.136

Preliminary study of frontal lobe 1H MR spectroscopy in childhood-onset schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2013.136

Brain metabolite abnormalities in the white matter of elderly schizophrenic subjects: implication for glial dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2013.136

Glutamatergic changes in the cerebral white matter associated with schizophrenic exacerbation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2013.136

Multimodal analysis of the hippocampus in schizophrenia using proton magnetic resonance spectroscopy and functional magnetic resonance imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2013.136

A short echo proton magnetic resonance spectroscopy study of the left mesial-temporal lobe in first-onset schizophrenic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2013.136

Thalamic glutamate levels as a predictor of cortical response during executive functioning in subjects at high risk for psychosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2013.136

Altered medial temporal activation related to local glutamate levels in subjects with prodromal signs of psychosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2013.136

Comparative study of proton and phosphorus magnetic resonance spectroscopy in schizophrenia at 4 Tesla

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2013.136

Striatal metabolic alterations in non-psychotic adolescent offspring at risk for schizophrenia: a (1)H spectroscopy study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2013.136

Glutamate dysfunction in people with prodromal symptoms of psychosis: relationship to gray matter volume.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2013.136

Higher levels of glutamate in the associative-striatum of subjects with prodromal symptoms of schizophrenia and patients with first-episode psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2013.136

Metabolite changes and gender differences in schizophrenia using 3-Tesla proton magnetic resonance spectroscopy (1H-MRS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2013.136

Glutamate levels in the associative striatum before and after 4 weeks of antipsychotic treatment in first-episode psychosis: a longitudinal proton magnetic resonance spectroscopy study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2013.136

Striatal glutamate and the conversion to psychosis: a prospective 1H-MRS imaging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2013.136

Ketamine effects on brain GABA and glutamate levels with 1H-MRS: relationship to ketamine-induced psychopathology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2013.136

Effects of ketamine on anterior cingulate glutamate metabolism in healthy humans: a 4-T proton MRS study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2013.136

Lack of effect of ketamine on cortical glutamate and glutamine in healthy volunteers: a proton magnetic resonance spectroscopy study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2013.136

Evaluation of NMDA receptors in vivo in schizophrenic patients with [123I]CNS 1261 and SPET: preliminary findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2013.136

Impact of schizophrenia and chronic antipsychotic treatment on [123I]CNS-1261 binding to N-methyl-D-aspartate receptors in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2013.136

First in vivo evidence of an NMDA receptor deficit in medication-free schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2013.136

Relationship between ketamine-induced psychotic symptoms and NMDA receptor occupancy: a [(123)I]CNS-1261 SPET study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2013.136

Consensus nomenclature for in vivo imaging of reversibly binding radioligands

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2013.136

N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2013.136

NMDA receptor channels: subunit-specific potentiation by reducing agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2013.136

N-Acetylcysteine--a safe antidote for cysteine/glutathione deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2013.136

N-acetylcysteine normalizes neurochemical changes in the glutathione-deficient schizophrenia mouse model during development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2013.136

Synaptic plasticity impairment and hypofunction of NMDA receptors induced by glutathione deficit: relevance to schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2013.136

Glutathione depletion in the brain disrupts short-term spatial memory in the Y-maze in rats and mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2013.136

Behavioral and biochemical effects of glutathione depletion in the rat brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2013.136

N-acetyl cysteine as a glutathione precursor for schizophrenia--a double-blind, randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2013.136

Medial temporal lobe glutathione concentration in first episode psychosis: a 1H-MRS investigation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2013.136

Schizophrenia: glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2013.136

Negative correlation between brain glutathione level and negative symptoms in schizophrenia: a 3T 1H-MRS study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2013.136

Validation of glutathione quantitation from STEAM spectra against edited 1H NMR spectroscopy at 4T: application to schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2013.136

Improved selectivity of double quantum coherence filtering for the detection of glutathione in the human brain in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2013.136

New double quantum coherence filter for localized detection of glutathione in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2013.136

Detection of head and neck cancer with 99Tc(m) glutathione: a correlative study with tissue glutathione and glutathione S-transferase levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2013.136

Translational characterization of [11C]GSK931145, a PET ligand for the glycine transporter type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2013.136

Biodistribution and radiation dosimetry of the glycine transporter-1 ligand 11C-GSK931145 determined from primate and human whole-body PET.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2013.136

Glycine transporter type 1 occupancy by bitopertin: a positron emission tomography study in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2013.136

The synthesis and preclinical evaluation in rhesus monkey of [¹⁸F]MK-6577 and [¹¹C]CMPyPB glycine transporter 1 positron emission tomography radiotracers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2013.136

Metabotropic glutamate receptors: potential drug targets for the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2013.136

Glutamate as a therapeutic target in psychiatric disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2013.136

Cell-type specificity of mGluR activation in striatal neuronal subtypes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2013.136

Metabotropic glutamate receptor 5 mediates the potentiation of N-methyl-D-aspartate responses in medium spiny striatal neurons.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2013.136

Potential psychiatric applications of metabotropic glutamate receptor agonists and antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2013.136

Synapse structure: glutamate receptors connected by the shanks

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2013.136

Shank, a novel family of postsynaptic density proteins that binds to the NMDA receptor/PSD-95/GKAP complex and cortactin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2013.136

Coupling of mGluR/Homer and PSD-95 complexes by the Shank family of postsynaptic density proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2013.136

ADX47273 [S-(4-fluoro-phenyl)-{3-[3-(4-fluoro-phenyl)-[1,2,4]-oxadiazol-5-yl]-piperidin-1-yl}-methanone]: a novel metabotropic glutamate receptor 5-selective positive allosteric modulator with preclinical antipsychotic-like and procognitive activiti

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2013.136

Dose-dependent effect of CDPPB, the mGluR5 positive allosteric modulator, on recognition memory is associated with GluR1 and CREB phosphorylation in the prefrontal cortex and hippocampus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2013.136

mGluR5 positive allosteric modulators facilitate both hippocampal LTP and LTD and enhance spatial learning

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2013.136

Metabotropic glutamate subtype 5 receptors modulate locomotor activity and sensorimotor gating in rodents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2013.136

Effect of antipsychotic treatment on the prepulse inhibition deficit of mGluR5 knockout mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2013.136

The mGluR5 antagonist MPEP, but not the mGluR2/3 agonist LY314582, augments PCP effects on prepulse inhibition and locomotor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2013.136

In vivo variation in metabotropic glutamate receptor subtype 5 binding using positron emission tomography and [11C]ABP688.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2013.136

Test-retest stability of cerebral mGluR₅ quantification using [¹¹C]ABP688 and positron emission tomography in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2013.136

In vivo positron emission tomography imaging with [¹¹C]ABP688: binding variability and specificity for the metabotropic glutamate receptor subtype 5 in baboons.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2013.136

Increased metabotropic glutamate receptor subtype 5 availability in human brain after one night without sleep.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2013.136

Reduced metabotropic glutamate receptor 5 density in major depression determined by [(11)C]ABP688 PET and postmortem study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2013.136

Kinetic analysis of the metabotropic glutamate subtype 5 tracer [(18)F]FPEB in bolus and bolus-plus-constant-infusion studies in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2013.136

18F-FPEB, a PET radiopharmaceutical for quantifying metabotropic glutamate 5 receptors: a first-in-human study of radiochemical safety, biokinetics, and radiation dosimetry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2013.136

Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2013.136

Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2013.136

A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2013.136

Mice lacking metabotropic glutamate receptor 5 show impaired learning and reduced CA1 long-term potentiation (LTP) but normal CA3 LTP

21 January 2018

1 reference

12 December 2020

Six-month treatment with atypical antipsychotic drugs decreased frontal-lobe levels of glutamate plus glutamine in early-stage first-episode schizophrenia

1 reference

12 December 2020

An in vivo proton magnetic resonance spectroscopy study of schizophrenia patients

1 reference

12 December 2020

Prefrontal dopamine D1 receptors and working memory in schizophrenia.

1 reference

12 December 2020

Effects of MK-801 on spontaneous and amphetamine-stimulated dopamine release in striatum measured with in vivo microdialysis in awake rats

1 reference

12 December 2020

Radiosynthesis and preclinical evaluation of 11C-ABP688 as a probe for imaging the metabotropic glutamate receptor subtype 5.

1 reference

12 December 2020

Imaging changes in glutamate transmission in vivo with the metabotropic glutamate receptor 5 tracer [11C] ABP688 and N-acetylcysteine challenge

1 reference

12 December 2020

Synthesis and evaluation of [18F]Fluorobutyl ethacrynic amide: a potential PET tracer for studying glutathione transferase

1 reference

12 December 2020

Characterization of [11C]RO5013853, a novel PET tracer for the glycine transporter type 1 (GlyT1) in humans.

1 reference

12 December 2020

The selective mGlu5 receptor antagonist MTEP, similar to NMDA receptor antagonists, induces social isolation in rats

1 reference

12 December 2020

Decreased frontal lobe ratio of N-acetyl aspartate to choline in familial schizophrenia: a proton magnetic resonance spectroscopy study

1 reference

12 December 2020

Duration of untreated psychosis and proton magnetic resonance spectroscopy (1H-MRS) findings in first-episode schizophrenia

1 reference

12 December 2020

Frontolimbic glutamate alterations in first episode schizophrenia: evidence from a magnetic resonance spectroscopy study

1 reference

12 December 2020

Observation of metabolic changes in chronic schizophrenia after neuroleptic treatment by in vivo hydrogen magnetic resonance spectroscopy

1 reference

12 December 2020

Grey matter and social functioning correlates of glutamatergic metabolite loss in schizophrenia

1 reference

12 December 2020

Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort.

1 reference

12 December 2020

Identifiers

DOI

10.1038/MP.2013.136

1 reference

26 June 2017

1 reference